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Abstract
The worldwide spread of H1N1 avian influenza and the increasing reports about its resistance to the current drugs have
made a high priority for developing new anti-influenza drugs. Owing to its unique function in assisting viruses to bind the
cellular surface, a key step for them to subsequently penetrate into the infected cell, hemagglutinin (HA) has become one of
the main targets for drug design against influenza virus. To develop potent HA inhibitors, the ZINC fragment database was
searched for finding the optimal compound with the core hopping technique. As a result, the Neo6 compound was
obtained. It has been shown through the subsequent molecular docking studies and molecular dynamic simulations that
Neo6 not only assumes more favorable conformation at the binding pocket of HA but also has stronger binding interaction
with its receptor. Accordingly, Neo6 may become a promising candidate for developing new and more powerful drugs for
treating influenza. Or at the very least, the findings reported here may provide useful insights to stimulate new strategy in
this area.
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Introduction
In recent years, severe flu-like human cases were reported
around the world and subsequently the causative virus was
identified as the influenza A virus [1,2]. The virus was spreading
rapidly around the world and had been identified as a new
reassortant with three genetic lineages, mainly with a swine origin.
Therefore, it was called swine-origin influenza virus (S-OIV).
Owing to its extremely rapid human-to-human transmission rate,
within only two months the 2009 S-OIV had been detected
throughout the entire world. On June 11th, 2009 the World
Health Organization (WHO) declared an official pandemic, the
first pandemic in the 21st century [3].
Influenza A virus that belongs to the Orthomyxoviridae family
is a negative-strand segmented RNA virus, in which the surface
membrane proteins are constituted by three important compo-
nents: M2 proton channel, hemagglutinin (HA), and neuramin-
idase (NA). The M2 proton channel is responsible for proton
conductance vitally important to viral replication. HA is
responsible for binding to the surface of the infected cell as a
trimer leading to the attachment and subsequent penetration by
viruses into the target cell. NA is responsible for cleaving the
terminal sialic acid moieties from the receptors to facilitate the
elution of the progeny virions from the infected cell [4]. Therefore,
any of the three components can be the target for drug design
against influenza virus. Recently, stimulated by the successful
determination of its high-resolution three-dimensional structure
[5], many discussions about the M2 channel have been made in
this regard [5,6,7,8,9]. The two existing M2 drugs, amantadine
(Symmetrel) [10] and rimantadine (Flumadine) [10] approved by
FDA, are no longer effective because of their inefficacies to
influenza virus.
Sialic acid (SA) as a natural ligand combines with both of the
glycoproteins (HA and NA) and located at the membrane of host
cell, which is the basis of heme-agglutination when viruses are
mixed with blood cells and entry of the virus into cells of the upper
respiratory tract [11,12]. According to the mutagenic analysis the
residues of both HA1 and NA binding sites are quite conserved for
most influenza A strains [13,14].
Owing to its deep active site cleft, the NA has been an attractive
target for drug design. Both zanamivir and oseltamivir were
designed by modifying the sialic acid (SA) structure. The two
FDA-approved clinical drugs were once successfully used to inhibit
the spread of influenza viral progeny [15] by binding to viral
surface glycoprotein of neuraminidase (NA) [15]. However, it has
also been found from several clinical cases [16,17,18] that
oseltamivir failed to treat avian influenza virus. It is both antigenic
drift (sequence base mutations) and antigenic shift (genetic
recombination) of segmented RNA genome of influenza viruses
that have caused the NA inhibitor being resistant [19,20].
HA facilitates viral entry through binding to the host surface
sialic acid residues [21]. Accordingly, if HA is blocked at its sialic
acid binding site by a small molecule, the viral entry process will be
stopped and the penetration of viruses into host cell prevented. In
comparison with NA inhibitors, the HA inhibitors were usually
more effective in inhibiting influenza virus. For all the HA
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the recent pandemic H1N1/09 virus was taken as the target for
constituent screening and drug design [23].
Despite of many year scientific research efforts, so far there is no
clinical available inhibitor against HA1. On the other hand, many
studies have indicated that computational approaches, such as
structural bioinformatics [24,25], molecular docking [26,27],
pharmacophore modeling [28], identification of proteases and
their types [29], and HIV protease cleavage site prediction
[30,31], can timely provide very useful information and insights
for drug development. Encouraged by the aforementioned studies,
the present study was initiated in an attempt to find a new anti-
influenza compound by screening the fragment database for the
optimal constituent inhibitor. Meanwhile, the techniques of the
core hopping with glide docking and molecular dynamic
simulation were also utilized to analyze the binding interactions
between the inhibitor and HA1, in hopes that the findings thus
obtained will be useful for developing new and powerful drugs
against H1N1 influenza virus.
Materials and Methods
1. Protein structure and the databases
The crystal structure for the HA1 subtype from the recent
pandemic H1N1/09 virus was downloaded from the PDB Bank
[32]. Its PDB ID is 3AL4. The antigenicity of the HA1 from the
swine-origin A (H1N1)-2009 influenza A virus is quite similar to
that of the HA from the 1918 pandemic virus [23]. The binding-
site was identified by the SiteMap tool in Schrodinger Suite 2009
(www.schrodinger.com) as described in [34,35,36]. The bind-site
encompassed the ligand N-Acetyl-D-Glucosamine (NAG), which is
observed in complex with HA1 of the crystal structure (PDB:
3AL4). Shown in Fig. 1 is a close-up view for the binding site of
protein HA1 rendered by the molecular surface. The binding
pocket is formed by those residues that have at least one heavy
atom (i.e., an atom other than hydrogen) with a distance ƒ5 A ˚
away from any heavy atom of NAG ligand when it is bound to the
receptor at the binding site, as elaborated in [37]. The segments of
loop1, loop2, loop3, and loop4, which play an important role in
the interactions with the ligand, are shown by four different colors
with their respective key residues: Ser92, Glu72, Pro143, and
Arg227 (Fig. 1). The motions of such four residues were
monitored during the molecular dynamics simulations.
The drug-like database and the fragment database derived from
ZINC [38] were used for virtual screening and core hopping
searching, respectively.
2. Virtual screening
The Glide5 docking program [39] interfaced with Schrodinger
Suite 2009 [33] was used to screen the drug-like database from
ZINC [38] based on the 3D structure of 3AL4. The preparation
and refinement protocols for protein receptor and all compound
structures were performed on the Protein Preparation Wizard and
LigPrep modules embedded in Schrodinger 2009 [33], respec-
tively. For protein preparation, the process included assigning
bond orders, adding hydrogen, treating metals, treating disulfides,
deleting waters and alleviating potential steric clashes, adjusting
bond order and formal charges by protein minimization with the
OPLS2005 force field [40], the constrained refinement value of
RMSD for the protein was limited to 0.3 A ˚. Meanwhile, for the
compounds, the preparation consisted of the generating possible
states by ionization at target pH 7.062.0, desalting, retaining
chiralities from 3D structure and geometry minimization with the
OPLS2005 force field [40]. When the above steps were
accomplished, all investigated compounds were docked into the
receptor pocket through the rigid docking model with the Stand-
precision (SP) scoring function [41,42] to estimate the binding
affinities.
3. Core hopping method
Many useful clues for drug design can be achieved through
molecular docking studies (see, e.g., [24,27,43,44,45,46]). In order
to gain even more useful information in this regard, the novel drug
design algorithm called ‘‘Core Hopping’’ [33] was used in this
study that has the function to perform both the fragment-based
replacing and molecular docking. Such method is particularly
useful for de novel drug design because it can improve the activity
of the template, which was ZINC01602230 compound in this
study. As a lead compound screened out from the drug-like
database, the template was taken as an initial structure to subject
to optimization via the core hopping method by finding the
optimal cores that are attached to the scaffold part of the template
in binding with the protein receptor.
During the process of core hopping, the first step was to define
the points at which the cores were attached to the scaffold. It was
performed in the Define Combinations Step from the Combina-
torial Screening panel [33]. The second step was to define receptor
grid file, which was done in the Receptor Preparation panel [33].
The third step was to prepare the cores attached to the scaffold for
the fragment database derived from ZINC [38]. Finally, the cores
thus obtained were sorted and filtered by goodness of alignment
and then re-docked into the receptor after attaching the scaffold,
followed by using the docking scores to sort the final molecules.
4. Molecular dynamics simulations
Many marvelous biological functions in proteins and DNA and
their profound dynamic mechanisms, such as switch between
active and inactive states [47,48], cooperative effects [49],
allosteric transition [50,51], intercalation of drugs into DNA
[52], and assembly of microtubules [53], can be revealed by
Figure 1. A close-up view for the binding site of HA1 (PDB ID:
3AL4). The binding pocket is defined by those residues that have at
least one heavy atom with a distance 5 A ˚ from the NAG ligand [37]. The
four loops (loop1, loop2, loop3, and loop4) that play an important role
in interacting with the ligand are represented by round ribbons of four
different colors as well as their key residues Ser92, Glu72, Pro143, and
Arg227, respectively. The motions of such four residues were monitored
during the molecular dynamic simulation. The docked poses for
ZINC01602230, Neo and Neo6 are shown with the stick model colored
in purple, yellow and dark green, respectively.
doi:10.1371/journal.pone.0028111.g001
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the action mechanism of a receptor with its ligand, we should
consider not only the static structures concerned but also the
dynamical information obtained by simulating their internal
motions or dynamic process.
In order to examine whether the designed inhibitor remains
bound in the presence of explicit solvent from a dynamic point of
view, the molecular dynamic simulation was performed with
GROMACS 96-53a6 force fields [55] with the periodic boundary
conditions (PBC) by using GROMACS 4.0 package for Linux.
The topology files and charges for the ligand atoms were
generated by the Dundee PRODRG2.5 Server (beta) [56]. Before
starting the simulations, all the models were solvated with the
explicit simple point charge (SPC) water in a cubic box. The
models were covered with a water shell of 1.0 nm from the surface
of the protein. The system was neutralized with six chlorine ions to
replace the six SPC water molecules. Subsequently, the energy
minimization was performed for the system concerned by using
the steepest descent until touching a tolerance of 100kJ/mol. And
then, the 10 ns MD simulations were carried out with a time step
of 1 fs; the corresponding coordinates were stored every 100 fs.
The PME algorithm was used to calculate the electrostatic
interactions. All simulations were run under the periodic boundary
condition with NVT ensemble by using Berensen’s coupling
algorithm for keeping the temperature at 310 K and pressure at
1atm. All bonds were constrained by using the LINCS algorithm.
The GROMACS 4.0 package was utilized to analyze the results.
Results and Discussion
1. Virtual screening and Core hopping
The drug-like database from ZINC [38] was screened by using
Glide5 for its near-optimal performance aimed on targeting the
HA1 receptor (PDB ID:3AL4). The top hit (ZINC01602230) or (2-
amino-N-(7H-purin-6-yl) acetamide) (Fig. 2), a compound
condensation product of Glycine and Adenine, which was
considered as the most potential lead compound for further
modification. Subsequently, the core hopping method was
employed to search the fragment database for replacing the
adenine part. Finally, the new structure Neo was discovered that
has more strong affinity than ZINC01602230.
The flowchart to show the process of finding the desired
inhibitor is given in Fig. 2, from which we can see that after the
ZINC01602230 was screened out from the Zinc drug-like
database, the core hopping method was used to optimize the
core1 to core2 by means of searching the ZINC fragment
database. The binding affinity between the NAG and the receptor
was used as the filtering set. As a result, the compound with the top
hits, Neo, was selected for further optimization.
As shown in Fig. 1, the rigid core2 fragment in Neo sticking out
of the active pocket might not well adhere to the active pocket
surface. To improve its binding affinity to the target protein, the
bond C-N was cut off at the site shown in Fig. 2.A sa
consequence of doing so, only the pyridine remained and the
whole structural flexibility was enhanced so as to have the ability
to stretch out to complement the surface of HA1 binding site.
The new scaffold as a building block was further optimized
through the second core hopping process by replacing the core3
with various fragments by searching the fragment database.
Interestingly, the best substitute core4 also contains the same
glycine as the terminal fragment on the other side of Neo or
Figure 2. The flowchart to show the inhibitor design process. The core1, core2, core3 and core4 were the key fragments for improving the
ligand binding affinity.
doi:10.1371/journal.pone.0028111.g002
Figure 3.The structures and docking scores list for the top ten
compound candidates modified from Neo and ZINC01602230.
doi:10.1371/journal.pone.0028111.g003
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modified from the Neo structure were generated, and then the top
ten compounds with the best binding affinity computed by Glide5
program [39,42] were listed in Fig. 3.
2. Interactions of the protein with Neo6
As can be seen from Fig. 4, the result obtained from the
docking simulation has proved that the compound binding
interactions with residues ARG227 and ASP92 were fully
consistent with the previous report [57]. The structure of Neo6
complemented the shallow pocket of HA1 with the optimal
conformation. The side chains of the key residues, such as Arg227,
Pro143, Glu72 and Asp92 in protein, made a major contribution
to the receptor-ligand binding affinity by forming H-bonds with
the different heavy atoms (e.g. O, N) of the Neo6 (Fig. 4). Besides
the common H-bonds formed between the three residues (Arg227,
Pro143, and Glu72) and the compound Neo6 as in [58], the other
two H-bonds were formed between the two nitrogen atoms of the
new extensible fragment core4 and the oxygen atom of Asp92
residue. Consequently, compared with ZINC01602230, the
binding affinity of Neo6 with the receptor was strengthened from
25.83 kcal/mol to 28.38 kcal/mol (Fig. 3).
3. Molecular dynamics trajectory analysis
Furthermore, molecular dynamics simulations were performed
for the inhibitor-complexed system HA1-Neo6 and the inhibitor-
uncomplexed system HA1, respectively. The root mean square
deviation (RMSD) from initial conformation is a central criterion
used to evaluate the difference of the protein system. The stability
of a simulation system was evaluated based on its RMSD. The
RMSD values for both Neo6-HA1 (green curve) and HA1 (red
curve) versus the simulation time were illustrated in Fig. 5A,i n
which the RMSD for Neo6-HA1 system is a little smaller than that
of HA1 system, indicating that the flexibility of HA1 was
decreased after the Neo6 binding to HA1. In order to investigate
the motions about the important residues interacted with the
inhibitor in the binding site defined as loops (Loop1–Loop4) in
Fig. 1, the root mean square fluctuations (RMSF) for all the side-
chain atoms of protein were calculated, as shown in Fig. 5B. The
curves of RMSF associated with Loop1, Loop2, Loop3, and
Loop4 are colored orange, light blue, dark blue, and maroon,
respectively. It can be clearly seen from Fig. 5 that the fluctuating
magnitudes of the four loops in HA1 are much larger than those in
Neo6-HA1, clearly indicating that the receptor HA1 is more stable
after binding with the ligand Neo6.
Figure 4. A close view to show the interaction of the receptor with the docked Neo6. (A) The yellow dotted lines indicate the H-bond
interactions of the receptor with Neo6. (B) The molecular surface is shown around the binding site of 3AL4; the hydrophobic surface is colored in
green and the hydrogen bond surface in purple. See the text for further explanation.
doi:10.1371/journal.pone.0028111.g004
Figure 5. Analysis of molecular dynamics simulations. (A) The RMSD for all backbone atoms of the Neo6-HA1 system (green) and the HA1
system (red). (B) The RMSF for side-chain atoms of the Neo6-HA1 system (green) and the HA1 system (red). The curves associated with Loop1, Loop2,
Loop3, and Loop4 are colored orange, light blue, dark blue, and maroon, respectively.
doi:10.1371/journal.pone.0028111.g005
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Neo6 is anticipated to be a promising drug candidate for further
experimental investigation to develop new and effective drug
against influenza viruses.
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